Teubert Selina, Borgardts Klara, Steindor Friedrich, Borrelli Maria, Schrader Stefan, Geerling Gerd, Spaniol Kristina
Department of Ophthalmology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf; and.
Department of Ophthalmology, Pius-Hospital Oldenburg, Carl von Ossietzky Universität Oldenburg.
Cornea. 2024 Oct 29;44(9):1119-1126. doi: 10.1097/ICO.0000000000003748.
To examine clinical results up to 10 years after Descemet Membrane Endothelial Keratoplasty (DMEK) and Triple-DMEK.
Prospective study including 201 eyes, of which 54 eyes [38 DMEKs and 16 Triple-DMEKs; Fuchs endothelial dystrophy (n = 45), pseudophakic bullous keratopathy (n = 9)] reached the minimum follow-up of 5 years and were followed up for up to 10 years. We evaluated best-corrected visual acuity (BCVA, logarithm of the minimum angle of resolution [logMAR]), endothelial cell density (ECD, cells/mm 2 ), minimal central corneal thickness (CCT, μm), central retinal thickness (μm), rebubbling, graft survival and re-DMEK rate, chamber angle alterations, and incidence of glaucoma.
Fifty-four eyes had a 5-year and 37 eyes an 8- to 10-year follow-up. Mean follow-up was 94.4 ± 12.1 months. Best-corrected visual acuity increased from 0.6 ± 0.3 logMAR to 0.1 ± 0.2 logMAR at 6 months ( P ≤ 0.001) and was 539 ± 54 μm at long term. Endothelial cell density decreased from 2488 ± 320.9 (donor) to 980.1 ± 437 cells/mm 2 with an average ECD loss/year of 4% and did not correlate with BCVA. Central corneal thickness decreased from 596.9 ± 82.2 μm to 498.6 ± 24.3 μm at 12 months ( P ≤ 0.001) and remained stable ( P = 1.000). Mean rebubbling rate was 0.3 ± 0.5/eye and did not correlate with BCVA. Eight eyes (14.8%) received at least 1 rebubbling. Primary graft failure/rejection rate was 1.5%/0% within the first postoperative year, and secondary graft failure rate was 12.4% at 7 years. Eight eyes (preoperative n = 3, de novo n = 5) had open-angle glaucoma without chamber angle changes (14.8%, P ≤ 0.001).
Although ECD decreases continuously in the long-term follow-up, excellent visual acuity can be preserved 10 years after DMEK and Triple-DMEK. The final outcome can be estimated 6 months after surgery.
观察后弹力层内皮角膜移植术(DMEK)和三联DMEK术后长达10年的临床效果。
前瞻性研究纳入201只眼,其中54只眼(38只DMEK和16只三联DMEK;Fuchs内皮营养不良45只眼,人工晶状体眼大泡性角膜病变9只眼)达到了5年的最短随访时间,并进行了长达10年的随访。我们评估了最佳矫正视力(BCVA,最小分辨角对数[logMAR])、内皮细胞密度(ECD,细胞/mm²)、中央角膜最小厚度(CCT,μm)、中央视网膜厚度(μm)、再次注气、植片存活和再次DMEK率、房角改变以及青光眼发病率。
54只眼进行了5年随访,37只眼进行了8至10年随访。平均随访时间为94.4±12.1个月。最佳矫正视力在术后6个月时从0.6±0.3 logMAR提高到0.1±0.2 logMAR(P≤0.001),长期时为539±54μm。内皮细胞密度从供体时的2488±320.9降至980.1±437细胞/mm²,平均每年ECD损失4%,且与BCVA无关。中央角膜厚度在术后12个月时从596.9±82.2μm降至498.6±24.3μm(P≤0.001),并保持稳定(P = 1.000)。平均再次注气率为0.3±0.5次/眼,且与BCVA无关。8只眼(14.8%)接受了至少1次再次注气。术后第1年原发性植片失败/排斥率为1.5%/0%,7年时继发性植片失败率为12.4%。8只眼(术前3只,新生5只)发生开角型青光眼且房角无改变(14.8%,P≤0.001)。
尽管在长期随访中ECD持续下降,但DMEK和三联DMEK术后10年仍可保持出色的视力。术后6个月即可预估最终结果。